CURRICULUM VITAE. Xiaodong Wang

Transcription

1 CURRICULUM VITAE Name: Contact: Xiaodong Wang The University of North Carolina at Chapel Hill Center for Integrative Chemical Biology and Drug Discovery Division of Medicinal Chemistry and Natural Products 2096 Genetic Medicine Building, CB #7363 Chapel Hill, NC Telephone: ; Fax: Education 5/2008-7/2008 Postdoctoral Research Fellow, Organic Chemistry Advisor: Professor David Lawrence University of North Carolina at Chapel Hill, NC 8/1997 9/2002 Ph.D. in Organic Chemistry Advisor: Professor Peter Wipf University of Pittsburgh, Pittsburgh, PA 9/1993 7/1996 M.S. in Organometallic Chemistry Advisor: Professor Shijie Lu Chinese Academy of Sciences, Lanzhou, China 9/1989 6/1993 B.S. in Polymer Chemistry Lanzhou University, Lanzhou Professional experience Research Associate Professor and Director of Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Division of Medicinal Chemistry, Eshelman School of Pharmacy, NC Research Assistant Professor and Assistant Director of Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Division of Medicinal Chemistry, Eshelman School of Pharmacy, NC Research Investigator I, Department of Medicinal Chemistry, Genomic Institute of the Novartis Research Foundation, San Diego, CA Research Scientist, Lead Optimization, Array BioPharma, Boulder, CO Staff Scientist, Lead Generation and Lead Optimization, Array BioPharma, Boulder, CO Honors 2001 Poster competition winner, Science 2001, University of Pittsburgh

2 2000 Wallace Prize, University of Pittsburgh Peer Reviewed Publications (* corresponding author) 1. Wang, A.*; Wang, X.; Lu, S.; Fu, H. Synthesis of a New Chiral Phosphine from D- Sorbitol Chinese Chem. Lett. 1996, 7, Lu, S.*; Wei, F.; Wang, X.; Wang, H.; Huang, L. Ligand Migrations During the Formation of Some Palladium-rhodium Heterodinuclear Complexes J. Organometal. Chem. 1996, 510, Wang, A.*; Lu, S.; Wang, X.; Zhou, H.; Chen, J.; Fu, H; Wang, H. New Chiral Bisphosphine-rhodium Catalyzed Asymmetric Hydroformylation of Alkenes Progress in Natural Sciences 1997, 7, Wipf, P.*; Wang, X. Solubilized Zirconocene Dihydride as a Promotor of Alkene Coupling Reactions Tetrahedron Lett. 2000, 41, Wipf, P.*; Wang, X. Diels-Alder Approaches to Ring-functionalized Cyclic b-amino Acids Tetrahedron Lett. 2000, 41, Wipf, P.*; Wang, X. A New Ligand Scaffold for Catalytic Asymmetric Alkylzinc Additions to Aldehydes Org. Lett. 2002, 4, Wipf, P.*; Wang, X. Parallel Synthesis of Oxazolines and Thiazolines by Tandem Condensation-cyclodehydration of Carboxylic Acids with Amino Alcohols and Aminothiols J. Comb. Chem. 2002, 4, Wipf, P.*; Pierce, J.; Wang, X. Investigation of Ligand Loading and Asymmetric Amplification in CHAOx-Catalyzed Diethylzinc Additions, Tetrahedron: Asymmetry 2003, 14, Lee. M.; Raguse, T. L.; Schinnerl, M.; Pomerantz, W. C.; Wang, X.; Wipf, P.; Gellman, S. H.* Origins of the High 14-Helix Propensity of Cyclohexyl-Rigidified Residues in β- Peptides, Org. Lett. 2007, 9, Liu, J.; Wang, X.* Microwave-Assisted, Divergent Solution-Phase Synthesis of 1,3,6- Trisubstituted Pyrazolo[3,4-d]pyrimidines, ACS Comb Sci 2011, 13 (4), Liu, J.; Yang, C.; Simpson, C.; DeRyckere, D.; Van, D. A.; Miley, M. J.; Kireev, D.; Norris-Drouin, J.; Sather, S.; Hunter, D.; Korboukh, V. K.; Patel, H. S.; Janzen, W. P.; Machius, M.; Johnson, G. L.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X.* Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia, ACS Med. Chem. Lett. 2012, 3, PMC Hutti, J. E.; Porter, M. A.; Cheely, A. W.; Cantley, L. C.; Wang, X.; Kireev, D.; Baldwin, A. S.; Janzen, W. P. Development of a High-Throughput Assay for Identifying Inhibitors of TBK1 and IKKepsilon. PloS one 2012, 7 (7), e PMC Zhang, W.; Liu, J.; Stashko, M. A.; Wang, X.* Efficient Solution-Phase Synthesis of 4,5,7-Trisubstituted Pyrrolo[3,2-d]pyrimidines. ACS Comb Sci 2012, 15 (1), PMC Schlegel, J.; Sambade, M. J.; Sather, S.; Moschos, S. J.; Tan, A. C.; Winges, A.; Deryckere, D.; Carson, C. C.; Trembath, D. G.; Tentler, J. J.; Eckhardt, S. G.; Kuan, P. F.; Hamilton, R. L.; Duncan, L. M.; Miller, C. R.; Nikolaishvili-Feinberg, N.; Midkiff, B. R.; Liu, J.; Zhang, W.; Yang, C.; Wang, X.; Frye, S. V.; Earp, H. S.; Shields, J. M.;

3 Graham, D. K.* MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest 2013, 123 (5), PMC Liu, J.; Zhang, W.; Stashko, M. A.; DeRyckere, D.; Cummings, C.T.; Hunter, D.; Yang, C.; Jayakody, C. N.; Cheng, N.; Simpson, C.; Norris-Drouin, J.; Sather, S.; Kireev, D.; Janzen, W. P.; Earp, H. S., Graham, D. K.; Frye, S. V.; and Wang, X.* UNC1062, a new and potent Mer inhibitor. Eur. J. Med. Chem. 2013, 65, PMC Christoph, S.; DeRyckere, D.; Schlegel, J.; Frazer, J. K.; Batchelor, L. A.; Trakhimets, A. Y.; Sather, S.; Hunter, D. M.; Cummings, C. T.; Liu, J.; Yang, C.; Kireev, D.; Simpson, C.; Norris-Drouin, J.; Hull-Ryde, E. A.; Janzen, W. P.; Johnson, G. L.; Wang, X.; Frye, S. V.; Earp III, H. S.; Graham, D. K.* UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo. Mol. Cancer Therap. 2013, 12 (11), PMC Zhang, W.; Zhang, D.; Stashko, M. A.; Deryckere, D.; Hunter, D.; Kireev, D.; Miley, M. J.; Cummings, C.; Lee, M.; Norris-Drouin, J.; Stewart, W. M.; Sather, S.; Zhou, Y.; Kirkpatrick, G.; Machius, M.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X.* Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors. J Med Chem (23), PMC Zhang, W.; McIver, A. L.; Stashko, M. A.; Deryckere, D.; Branchford, B. R.; Hunter, D.; Kireev, D.; Miley, M. J.; Norris-Drouin, J.; Stewart, W. M.; Lee, M.; Sather, S.; Zhou, Y.; Di Paola, J. A.; Machius, M.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X.* Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis. J Med Chem (23), PMC Zhang, W.; DeRyckere, D.; Hunter, D.; Liu, J.; Stashko, M. A.; Minson, K. A.; Cummings, C. T.; Lee, M.; Glaros, T. G.; Newton, D. L.; Sather, S.; Zhang, D.; Kireev, D.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.*; Wang, X.* UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. J Med Chem 2014, 57 (16), PMC Wang, X., & Frye, S. (2014). Mer Receptor Tyrosine Kinase: Therapeutic Opportunities in Oncology, Virology, and Cardiovascular Indications. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, Da, C.; Stashko, M.; Jayakody, C.; Janzen, W. Wang, X.; Frye, S.; Kireev, D.* Discovery of Mer kinase inhibitors by Virtual Screening using Structural Protein-Ligand Interaction Fingerprints. Bioorg. Med. Chem. 2015, 23(5), PMC Lee-Sherick, A.; Zhang, W.; Menachof, K.; Hill, A.; Rinella, S.; Kirkpatrick, G.; Stashko, M.; Jordan, C.; Wei, Q.; Liu, J.; Zhang, D.; DeRyckere, D.; Wang, X.; Frye, S.; Earp, H.; and Graham, D.* Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget, 2015, 6 (9), PMC Cummings, C. T.; Zhang, W.; Davies, K. D.; Kirkpatrick, G. D.; Zhang, D.; DeRyckere, D.; Wang, X.; Frye, S. V.; Earp, H. S.; Graham, D. K.* Small Molecule Inhibition of MERTK Is Efficacious in Non Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Mol Cancer Ther 2015, 14 (9), Zhang, D.; Zheng, H.; Wang, X.* General and Cost-effective Synthesis of 1- Heteroaryl/arylcycloalkylamines and Their Broad Applications. Tetrahedron 2016, 72 (16),

4 25. Minson, K. A.; Smith, C. C.; DeRyckere, D.; Libbrecht, C.; Lee-Sherick, A. B.; Huey, M. G.; Lasater, E. A.; Kirkpatrick, G. D.; Stashko, M. A.; Zhang, W.; Jordan, C. T.; Kireev, D.; Wang, X.; Frye, S.; Earp, H. S.; Shah, N. P.; Graham, D. K.* The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight 2016, 1 (3). PMC Zhang, Y.; Chen, Z.; Zhao, J.; Tian, Q.; Wang, X.* Total Synthesis of Schisandra Nortriterpenoids: History, Progress and Perspective. Studies in Natural Products Chemistry, in press. 27. DeRyckere, D.; Sherick, A. B. L.; Huey, M. G.; Hill, A. A.; Tyner, J. W.; Jacobsen, K. M.; Page, L. S.; Kirkpatrick, G. D.; Eryildiz, F.; Montgomery, S. A., Zhang, W.; Wang, X.; Frye, S. V.; Earp, H. S.; Graham, D. K.* UNC2025, a MerTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clin Cancer Res 2016, Wang, X.;* Liu, J.; Zhang, W.; Stashko, M. A.; Nichols, J.; Miley, M. J.; Norris-Drouin, J.; Chen, Z.; Machius, M.; DeRyckere, D.; Wood, E.; Graham, D. K.; Earp, H. S.; Kireev, D.; Frye, S. V., Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. ACS Med Chem Lett 2016, 7 (12), PMC Sufit, A.; Lee-Sherick, A. B.; DeRyckere, D.; Rupji, M.; Dwivedi, B.; Varella-Garcia, M.; Pierce, A. M.; Kowalski, J.; Wang, X.; Frye, S. V., Earp, H. S.; Keating, A. K.;* Graham, D. K.* MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. PloS one 2016, 11 (10), e PMC McIver, A.; Zhang, W.; Liu, Q.; Jiang, X.; Stashko, M.; Nichols, J.; Miley, M.; Norris- Drouin, J.; Machius, M.; DeRyckere, D., Wood, E.; Graham, D. K.; Earp, H. S.; Kireev, D.; Frye, S. V., Wang, X.* Discovery of Macrocyclic Pyrimidines as MerTK-specific Inhibitors. ChemMedChem 2017, 12, Patents 1. Chianelli, D.; Cow, C. N.; He, Y.; Jiang, S.; Li, X.; Liu, X.; Liu, Z.; Loren, J.; Molteni, V.; Nabakka, J.; Ren, P.; Sim, T.; Wang, X.; You, S. Naphthyridinone compositions and methods for modulating c-kit and PDGFR receptors and their preparation. PCT Int. Appl. (2008), 155pp. WO , US 2008/ A1. 2. Ren, P.; Wang, X.; He, Y.; Okram, B.; Wang, X.; Zhang, G.; Liu, Z.; Liu, Y. Albaugh, P. A. Preparation of substituted pyrazolopyrimidinamines as protein kinase inhibitors. PCT Int. Appl. (2008), 63pp. WO (A2), , US2008/056523, CAN 149: AN 2008: Ren, P.; Wang, X.; Jiang, S.; Nagle, A.; Okram, B.; He, Y.; Xie, Y.; Wang, X.; Huang, S.; Wang, X.; Liu, Y. Albaugh, P. A.; Gray, N. S.; Zhang, G. Preparation of pyrrolo[2,3- b]pyridinecarboxamides as protein kinase inhibitors. PCT Int. Appl. (2008), 86pp. WO A AN 2008: Gwaltney, S. L.; Stafford, J. A.; Wallace, M.; Burgess, L. E.; Cowen, S. D.; Gonzales, S. S.; Laird, E. R.; Wang, X. Preparation of isoquinoline derivatives as dipeptidyl peptidase inhibitors. US2010/ B1, 63pp.

5 5. Wang, X.; Liu, J.; Yang, C.; Zhang, W.; Frye, S.; Kireev, D. Pyrazolopyrimidine compounds for the treatment of cancer. PCT/US2011/036215, WO A1, US2012/ , US B2 (Issued on March 22, 2016); US Wang, X.; Liu, J.; Zhang, W.; Frye, S.; Kireev, D. Pyrrolopyrimidine compounds for the treatment of cancer. PCT/US2012/058298, WO A1, US2013/641729, US (Issued on March 1, 2016), ZL (Issued on Dec 12, 2016). 7. Wang, X.; Zhang, W.; Kireev, D. Zhang, D.; McIver, A. Pyrimidine compounds for the treatment of cancer. PCT/US2013/42033, WO A1, US (received a Notice of Allowance on Dec. 2016). 8. Wang, X.; Liu, J.; Yang, C.; Zhang, W.; Frye, S.; Kireev, D. Pyrazolopyrimidine compounds for the treatment of cancer. PCT/US2013/065192, WO , EP , US (received a Notice of Allowance on April 2017). 9. Wang, X.; Zhang, W.; Frye, S.; Kireev, D.; McIver, A. L.; Liu, J. Pyrimidine compounds for the treatment of cancer. PCT/US2013/071409, WO Wang, X.; Zhang, W.; Frye, S.; Kireev, D. MerTK-specific pyrrolopyrimidine compounds. PCT/US2015/024362, WO A1, EP Wang, X.; Frye, S. MerTK-specific pyrazolopyrimidine compounds. PCT/US2015/024328, WO A Wang, X.; Zhang, D.; Frye, S.; Kireev, D. MerTK-specific pyrimidine compounds. PCT/US2015/024301, WO A1, EP Wang, X.; Zhang, W.; Frye, S. Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity. PCT/US2015/024381, WO A1. US (Issued on April 2017). 14. Wang, X.; Zhang, W.; Frye, S. Therapeutic uses of selected pyrimidine compounds with anti- Mer tyrosine kinase activity. PCT/US2015/024380, WO A1, US (Issued on May 16, 2017). 15. Wang, X.; Frye, S. Therapeutic uses of selected pyrazolopyrimidine compounds with anti- Mer tyrosine kinase activity. PCT/US2015/024373, WO A1, US (Issued on April 2017). 16. Earp, S.; Wang, X.; Frye, S. Methods for the treatment of tumors. PCT/US2015/024258, WO A Boxer, M. B.; Rohde, J. M.; Pragani, R.; Lu, L.; Davis, M. I. E.; Brimacombe, K. R.; Shen, M.; Simeonov, A.; Karavadhi, S.; Urban, D. J.; Jadhav, A.; Wang, X.; McIver, A. L. Mutant IDH1 inhibitors useful for treating cancer. PCT/US2015/ Wang, X.; Zhang, D.; Kireev, D. Novel Pan-TAM inhibitors and Mer/Axl dual inhibitors. PCT/US2016/054840, WO Wang, X.; Zheng, H.; Zhao, J.; Zhang, W.; Frye, S. Alkyl pyrrolopyrimidine analogs and methods of making and using same. Provisional filed on November, Abstracts of Meeting Presentations/Posters 1. Wang, X.; Wipf, P. Syntheses and Applications of New Chiral Ligands. 222 nd American Chemical Society National Meeting, Chicago, Illinois, Aug. 28, (presentation) 2. Wang, X.; Liu, J.; Yang, C.; Simpson, C.; Van Deusen, A.; Norris-Drouin, J.; Janzen, W.; Kireev, D.; Frye, S.; DeRychere, D; Graham, D.; Hunter, D.; Earp, H. S. Discovery of novel small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic

6 leukemia. 242 nd American Chemical Society National Meeting, Denver, CO, Aug. 28, (presentation) 3. Christoph, S.; DeRyckere, D.; Sather, S.; Wang, X.; Kireev, D.; Janzen, W.; Liu, J.; Yang, J.; van Deusen, A.; Simpson, C.; Norris-Drouin, J.; Frye, S.V.; Earp, H.S.; Johnson, G.L.; Graham, D.K. UNC569 a novel small molecule Mer receptor tyrosine kinase inhibitor for treatment of ALL. American Society of Hematology Annual Meeting. Blood 118: Abstract 614, (poster) 4. Christoph, S.; DeRyckere, D.; Sather, S.; Wang, X.; Kireev, D.; Janzen, W.; Liu, J.; Yang, J.; van Deusen, A.; Simpson, C.; Norris-Drouin, J.; Frye, S.V.; Earp, H.S.; Johnson, G.L.; Graham, D.K. (2012) UNC569 a novel small molecule Mer receptor tyrosine kinase inhibitor for treatment of ALL. German Society for Hematology and Oncology Meeting. Onkologie 35 (supplement 6): 185, (poster) 5. Schlegel, J.; Sambade, M.; Sather, S.; Carson, C.; Moschos, S.; Trembath, D.; Winges, A.; Wang, X.; Kireev, D.; Janzen, W.; Liu, J.; Yang, C.; Earp, H.S.; Frye, S.V.; DeRyckere, D.; Schields, J.; and Graham, D.K. Mer silencing by shrna or inhibition with a novel small molecule tyrosine kinase inhibitor abrogates Mer oncogenic properties in cell culture and animal models of melanoma. 9 th International Congress of the Society for Melanoma Research, (poster) 6. Christoph, S.; DeRyckere, D.; Schlegl, J.; Sather, S.; McGranahan, A.; Frasier, J.K.; Trakhimets, A.; Wang, X.; Kireev, D.; Janzen, W.; Liu, J.; Yang, J.; van Deusen, A.; Simpson, C.; Norris-Drouin, J.; Frye, S.V.; Earp, H.S.; Johnson, G.L.; Graham, D.K. Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo. American Society of Hematology Annual Meeting. Blood 120: Abstract 2607, (poster) 7. Branchford, B.; Law, L.; Sather, S.; Brodsky, G.; Earp, H. S.; Wang, X.; Frye, S.; Graham, D. K.; and DiPaola, J. A. A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, imer, the Novel MerTK Splice Variant. American Society of Hematology 54th Annual Meeting. Atlanta, GA. Blood 120: 3303, (poster) 8. Wang, X.; Liu, J.; Yang, C.; DeRyckere, D.; Christoph, S.; Simpson, C.; Miley, M. J.; Kireev, D.; Norris-Drouin, J.; Sather, S.; Hunter, D.; Janzen, W. P.; Machius, M.; Johnson, G. L.; Earp, H. S.; Graham, D. K.; Frye, S. V. Discovery of UNC569 A Small Molecule Mer Kinase Inhibitor for the Treatment of Pediatric Acute Lymphoblastic Leukemia. the 2012 "Medicinal Chemistry" Gordon Research Conference, New London, NH, August, (poster) 9. Zhang, W.; Wang, X. Efficient and eco-friendly synthesis of dihydropyrimidonyl-4-phenyl boronic acid and application in Suzuki Miyaura cross coupling reaction. 244th American Chemical Society National Meeting, Philadelphia, PA, Aug (poster) 10. Zhang, W.; Liu, J.; Stashko, M. A.; DeRyckere D; Norris-Drouin J.; Hunter D.; Zhou Y.; Earp H. S.; Kireev D.; Graham D. K.; Janzen W. P.; Frye S. V.; Wang, X. Design and synthesis substituted 2,4- iaminopyrimidine-5-amides as novel Mer inhibitors for the treatment of acute lymphoblastic leukemia (ALL). 244th American Chemical Society National Meeting, Philadelphia, PA, Aug (poster) 11. Wang, X.; Liu, J.; Zhang, W.; Stashko, M. A.; DeRyckere, D.; Cummings, C.; Hunter, D.; Simpson, C.; Norris-Drouin, J.; Sather, S.; Kireev, D.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V. Novel Small Molecule Mer Kinase Inhibitors for the Treatment of cancer.

7 Drug Discovery & Therapy World Congress 2013, PLENARY LECTURES, 129, Boston, MA, June, (presentation) 12. Zhang, W.; McIver, A.; Zhang, D.; Kireev, D. B.; Stashko, M. A.; DeRycke, D.; Norris- Drouin, J. L.; Machius, M.; Miley, M.; Janzen, W.; Earp, H. S., III; Graham, D. K.; Frye, S. V.; Wang, X. Structure-based design and synthesis of novel pyrimidine analogs as Mer kinase inhibitors in the treatment of cancer. 246th American Chemical Society National Meeting & Exposition, Indianapolis, Indiana, (presentation) 13. Zhang, W.; McIver, A.; Kireev, D. B.; Stashko, M. A.; DeRycke, D.; Norris-Drouin, J. L.; Machius, M.; Miley, M.; Janzen, W.; Earp, H. S., III; Graham, D. K.; Frye, S. V.; Wang, X. Structure-based design and synthesis of novel 2,4-diaminopyrimidine analogs as Mer kinase inhibitors in the treatment of cancer. 246th American Chemical Society National Meeting & Exposition, Indianapolis, Indiana, (poster) 14. Schlegel, J.; Sambade, M.; Sather, S.; Moschos, S.; Tan, A-C.; Winges, A.; DeRyckere, D.; Carson, C. C.; Trembath, D. G.; Tentler, J. J.; Eckhardt, S. G.; Kuan, P.-F.; Hamilton, R. L.; Duncan, L. M.; Miller, C. R.; Nikolaishvili-Feinberg, N.; Midkiff, B. R.; Wang, X,; Liu, J.; Zhang, W.; Yang, C.; Frye, S.V.; Earp, H. S.; Shields, J.; and Graham, D. K. Mer receptor tyrosine kinase is a novel therapeutic target in melanoma Annual Meeting of the American Association of Cancer Researchers, Washington DC, (poster) 15. Branchford, B. R.; Law, L.; Sather, S.; DeRyckere, D.; Brodsky, G.; Earp, H. S.; Wang, X.; Frye, S.; Graham, D. K. and DiPaola, J. A. Inhibition of the Gas6/Mer Pathway with novel compounds recapitulates the antithrombotic phenotype of Gas6 -/- or Mer -/- mice in arterial and venous thrombosis models. XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, Netherlands, (poster) 16. Christoph, S.; Maag, S.; DeRyckere, D.; Graham, D. K.; Frye, S. V.; Earp, H. S.; Liu, J.; Yang, C.; Zhang, W.; Wang, X.; Beelen, D.; and Elmaagacli, A. H. Preclinical evaluation of UNC1062, a novel small molecule Mer inhibitor for the treatment of multiple myeloma. Annual Meeting of the German, Austrian, and Swiss Associations of Hematology and Oncology. Vienna, Austria. Onkologie, (poster) 17. Graham, D. K.; DeRyckere, D.; Lee-Sherick, A. B.; Winges, A.; Wang, X.; Zhang, W.; Liu, J.; Frye, S. V.; and Earp III, H. S. MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia. American Association of Cancer Researchers Pediatric Cancer at the Crossroads Conference. San Diego, CA, (poster) 18. DeRyckere, D.; Wang, X.; Winges, A.; Zhang, W.; Stashko, M. A.; Sather, S.; Cummings, C.; Janzen, W. P.; Frye, S. V.; Earp, H. S.; and Graham, D. K. Development of a novel small molecule inhibitor of the Mer tyrosine kinase for treatment of acute lymphoblastic leukemia. American Society of Hematology Annual Meeting. New Orleans, LA. Blood 122(21):2666, (poster) 19. Lee-Sherick, A. B.; Menachof, K.; Hill, A. A.; Rinella, A.; Liu, J.; DeRyckere, D.; Wang, X.; Frye, S. V.; Earp, H. S.; and Graham, D. K. UNC16666, a dual Mer and Flt-3 tyrosine kinase small molecule inhibitor in acute myeloid leukemia. American Society of Hematology Annual Meeting. New Orleans, LA. Blood 122(21):3849, (poster) 20. Christoph, S.; Maag, S.; DeRyckere, D.; Graham, D. K.; Frye, S. V.; Earp, H. S.; Liu, J.; Yang, C.; Zhang, W.; Wang, X.; Elmaagacli, A. H.; and Beelen, D. Mer receptor tyrosine kinase is a novel therapeutic target in multiple myeloma. American Society of Hematology Annual Meeting. New Orleans, LA. Blood 122(21):1957, (poster)

8 21. Acevedo, G.; Branchford, B. R.; Brzezinski, C.; Sather, S.; Brodsky, G.; DeRyckere, D.; Zhang, W.; Liu, J.; Earp, H. S.; Wang, X.; Frye, S. V.; Graham, D. K.; and DiPaola, J. Novel small molecule inhibitors of the Gas6/TAM signaling pathway inhibit platelet aggregation in vitro and protect mice from arterial and venous thrombosis in vivo. American Society of Hematology Annual Meeting. New Orleans, LA. Blood 122(21):2296, (poster) 22. DeRyckere D, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, and DK Graham. (2014) Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia. American Association of Cancer Researchers Annual Meeting. San Diego, CA. Abstract # Cummings CT, Davies KD, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, and DK Graham. (2014) Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer. American Association of Cancer Researchers Annual Meeting. San Diego, CA. Abstract # Jacobsen KM, DeRyckere D, Zhang W, Wang X, Frye SV, Earp HS, and DK Graham. (2014) Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer. American Association of Cancer Researchers Annual Meeting. San Diego, CA. Abstract # Lee-Sherick A, Menachof K, Hill A, Rinella S, DeRyckere D, Liu J, Wang X, Frye S, Earp HS, and D Graham. (2014) A dual FLT-3 and MER tyrosine kinase small molecule inhibitor in acute myeloid leukemia cell lines and patient samples. American Association of Cancer Researchers Annual Meeting. San Diego, CA. Abstract # Newton TP, Cummings CT, Kirkpatrick GD, Hinz TK, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Heasley L, and DK Graham. (2014) A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition. American Association of Cancer Researchers Annual Meeting. San Diego, CA. Abstract # Teodorovic LS, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Eckhardt SG, Earp HS, Graham DK. (2014) Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant melanoma cell lines. American Association of Cancer Researchers Annual Meeting. San Diego, CA. Abstract # Minson KA, Lee-Sherick A, DeRyckere D, Wang X, Frye SV, Earp HS, and Graham DK. (2014) Pre-Clinical Evaluation of Novel FLT3 inhibitors effective in FLT3-ITD AML American Society of Pediatric Hematology/Oncology 27 th Annual Meeting. Chicago, IL. Abstract # Graham DK, DeRyckere D, Wang X, Hill AA, Zhang W, Frye SV, and Earp HS. (2014) UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemia. 26 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Barcelona, Spain. Abstract # DeRyckere D, Lee-Sherick AB, Hill AA, Page L, Wang X, Frye SV, and Earp HS. (2014) UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia. American Society of Hematology 56 th Annual Meeting. San Francisco, CA. Blood 124(21): Minson KA, Smith CC, Lee-Sherick AB, 89, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. (2014) MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with

9 Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia. American Society of Hematology 56 th Annual Meeting. San Francisco, CA. Blood 124 (21): Graham DK, DeRyckere D, Minson KA, Smith CC, Hill AA, Huey M, Lasater EA, Wang X, Shah NP, Frye SV, Earp HS. (2015) Development of novel small molecule MerTK and FLT3 tyrosine kinase inhibitors for treatment of acute leukemia. 13 th International Congress on Targeted Anticancer Therapies. Paris, France. Ann Oncol 26(Suppl 2):ii Minson KA, Smith CC, Lee-Sherick AB, Librecht C, DeRyckere D, Lasater EA, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. (2015) MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia. The American Society of Pediatric Hematology/Oncology 28 th Annual Meeting. Phoenix, AZ. Abstract # Xiaodong Wang (2016) Novel Small Molecule MerTK Inhibitors for the Treatment of Cancer Mogan Mountain International Summit on Green Pharmaceutical. Deqing, China. (session Chair) (Presentation).